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ABSTRACT 
Objective: A new series of 2-{4-(t-amino)-2-(but-2-yn-1-yl)}-1,3-benzothiazole derivatives, 2-[4-(pyrrolidin-1-yl)but-2-yn-1-yl]-1,3-benzothiazole 
(BZ2), 2-[4-(2-methylpiperidin-1-yl)but-2-yn-1-yl]-1,3-benzothiazole (BZ3), 2-[4-(piperidin-1-yl) but-2-yn-1-yl]-1,3-benzothiazole (BZ4), 2-[4-
(azepan-1-yl)but-2-yn-1-yl]-1,3-benzothiazole (BZ5), 2-[4-(4-methylpiperazin-1-yl) but-2-yn-1-yl]-1,3-benzothiazole (BZ6), 2-[4-(2, 6-
dimethylpiperidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole (BZ7) were synthesized and screened in vitro as potential antimicrobial agents.  
Methods: In-vitro antimicrobial activity evaluation was done, by agar diffusion method and broth dilution test against Staphylococcus aureus ATCC 
6538p, Candida albicans ATCC 10231, Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 8739, and Bacillus subtilis ATCC 6633. Minimum 
inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) were determined. The results of antimicrobial testing were 
compared to two positive control drugs ciprofloxacin (5 µg/ml) and fluconazole (500µg/ml).  
Results: Compound 2-[4-(azepan-1-yl) but-2-yn-1-yl]-1,3-benzothiazole (BZ5) showed the highest antibacterial activity against S. aureus with MIC 
value of 15.62 µg/ml while; Compound 2-[4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]-1,3-benzothiazole (BZ7) exhibited the highest 
antibacterial activity against P. aeruginosa with MIC value of 31.25 µg/ml. Compounds 2-[4-(pyrrolidin-1-yl)but-2-yn-1-yl]-1,3-benzothiazole 
(BZ2) and 2-[4-(azepan-1-yl)but-2-yn-1-yl]-1,3-benzothiazole (BZ5) showed the highest antifungal activity against C. albicans with MIC value of 
15.62 µg/ml (for both).  
Conclusion: The results obtained showed variation in the antibacterial and antifungal activity based on the structure of the cyclic amines in these 
amino acetylenic benzothiazole derivatives.  
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INTRODUCTION 
Microbes are the causative agents of various types of infectious 
diseases like pneumonia [1], amebiasis [2], typhoid [3], malaria [4], 
common cold [5], influenza [6], syphilis and AIDS [7]. The majority 
of microbes causing these infections have been developed resistance 
against the commonly used antimicrobial agents [8], so searching for 
new antimicrobial agents is crucial, among various heterocyclic 
derivatives that act as antimicrobial agents were the benzothiazole 
derivatives. In one study [9] which compares the potency between 
oxazole and benzothiazole derivatives for antibacterial and 
antifungal activity against Escherichia coli, Staphylococcus aureus 
and Pseudomonas aeruginosa for antibacterial activity, and for 
antifungal activity against Aspergillus niger and Candida albicans. 
Benzothiazole derivative 1 was found more potent than oxazole 
derivative 2 in both antibacterial and antifungal activity.  
 
 
Fig. 1: The structure of benzothiazole derivative (compound 1) 
and oxazole derivative (compound 2) 
Another series of substituted benzothiazole derivatives were found 
to be associated with a different antibacterial activity such as 
compounds 3 and 4. Both exhibited high antibacterial activity 
against drug-resistant Gram-positive bacteria. Some of these 
benzothiazoles are active against Enterococcus faecalis [10].  
 
 
Fig. 2: The structure of substituted benzothiozole derivatives 
(compound 3 and 4) 
 
As a result of reviewing the investigational drugs used as 
antimicrobial agents [11, 12]. We envision a unique and new series 
of benzothiazole derivatives, namely 2-{4-(t-amino)-2-(Burt-2-in-1-
yl)}-1, 3-benzothiazoles based on the concept of the fractional based 
analysis with the following unique substitutes. Benzothiazole ring as 
a directing moiety towards different sites in bacteria and fungi that 
lead to antimicrobial activity, intensify the effect by the amino 
acetylenic link which provides the following binding interaction. The 
cyclic amino group provides ionic or hydrogen bonding with various 
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sites in bacteria or fungi, a similar acetylenic group for electrostatic 
interaction and the 2-butyl to provide the appropriate distance 
between benzothiazole moiety and the cyclic amine. These forces of 
interaction expected to provide the potential antimicrobial 
activity. Our preliminary antimicrobial evaluation was in 
agreement with the design of this unique series of amino 
acetylenic benzothiazoles.  
MATERIALS AND METHODS  
Experimental 
Chemicals 
The following chemicals and materials were used: Benzothiazole 
(Sigma-Aldrich, St. Louis, U. S. A), Piperidine (Sigma-Aldrich, St. 
Louis, U. S. A), Propargyl bromide (Sigma-Aldrich, St. Louis, U. S. A), 
2-Methylpiperidine (Sigma-Aldrich, St. Louis, U. S. A), 2, 6-Dimethyl-
piperidine (Sigma-Aldrich, St. Louis, U. S. A), Pyrrolidine (Sigma-
Aldrich, St. Louis, U. S. A), 1-Methyl-piperazine (Sigma-Aldrich, St. 
Louis, U. S. A), Hexamethylenamine (Sigma-Aldrich, St. Louis, U. S. A), 
DMSO (Sigma-Aldrich, St. Louis, U. S. A), Potassium carbonate 
anhydrous, Chloroform, Ethanol (Sd Fine Chem Ltd), Cuprous 
Chloride, 1,4-Dioxane (Full Time Chemicals, Anqing, China), 
Acetonitrile (SDFCL Chemicals, Mumbai, India), Paraformaldehyde 
(BDH Chemicals, Pennsylvania, U. S. A), Distilled water, Dimethyl 
sulfoxide-d6 (Sigma-Aldrich, St. Louis, U. S. A) and Tetramethyl 
silane (Sigma-Aldrich, St. Louis, U. S. A).  
Culture media 
Muller Hinton Agar, Muller Hinton Broth, Sabouraud’s Dextrose 
Agar, and Sabourauds Dextrose Broth were obtained from Oxoid 
Laboratories (Hampshire, U. K).  
Instrumentation 
The structures of the synthesized compounds were confirmed by IR, 
1H-NMR, [13]C-NMR, DSC and elemental analysis. Melting points 
were determined on Gallenkamp Melting point Apparatus 
(California, U. S. A). Infrared (IR) spectra were recorded on Bruker 
FT-IR spectrophotometer (Massachusetts, U. S. A), using KBr discs 
and values were represented in cm-1. 1H-NMR and [13]C-NMR 
spectra were measured on a Varian 300 MHz spectrometer (Illinois, 
U. S. A) and DMSO-d6 as a solvent with TMS (Tetramethyl silane) as 
the internal standard. 1H data are reported in order: multiplicity (br, 
broad; s, singlet; d, doublet; t, triplet; m, multiplet). The elemental 
analysis was performed for C, H, N using (Euro EA elemental 
analyzer, Milan, Italy). The results obtained had a maximum 
deviation of (+2.59 to-2.95) from the theoretical value, which is 
considered within the acceptable variation range in results (±4. 4 
%). This variation range is set according to the accuracy of Euro EA 
Elemental Analyzer device. DSC thermogram measurement was 
carried out by using the DSC 1 Stare System v.11. ox (Mettler Toledo, 
Zürich, Switzerland). ChemBioDraw (Massachusetts, U. S. A) was 
used in the drawing of our schemes.  
Synthesis of 2-(prop-2-yn-1-yl)-1,3-benzothiazole (BZ1)  
A mixture of Propargyl bromide (1.88 g, 15.8 mmol) in Acetonitrile 
(10 ml) was added to the mixture of Benzothiazole (1.93 g, 13.2 
mmol) and Potassium carbonates anhydrous (2.18 g, 15.88 mmol) in 
Acetonitrile (20 ml). The reaction mixture was heated and stirred 
under reflux for 80 min. After cooling, the insoluble residue was 
removed by filtration, and then the solvent was removed under 
reduced pressure. After that, 30 ml chloroform and 20 ml Distilled 
water (D. W) were added, and the filtrate was extracted using a 
separatory funnel. The organic layer was concentrated by the removal 
of chloroform under reduced pressure to afford the desired orange 
powder compound BZ1 C10H7NS in 1.4 gm, 80% yield; IR (KBr cm-1): 
3075, 2913, (ArH, stretch), 2294 (C≡CH, stretch), 1611, 1423 (Ar, C=C, 
stretch), 1252, 1109, 1019 (Ar, C=C, bending), 893, 750 (ArH, 
bending).1H-NMR (DMSO-d6): δ 2.49 (s, 1H, C≡ CH), 3.38 (s, 2H, CH2-
C≡), 6.8-7.1 (m, 4H, ArH).[13]C-NMR (DMSO-d6): 62 (CH2), 74 (CH), 81 
(C≡CH), 114, 116, 122, 124, 132, 151(Ar, C), 174 (N=C-S).  
Elemental analysis: Calcd. for C10H7NS: C, 63.47%; H, 3.73%; N, 
7.40%, found C, 63.24%; H, 3.51%; N, 7.31%.  
Synthesis of 2-{4-(t-amino)-2-(but-2-yn-1-yl)}-1, 3-benzo-
thiazole derivatives (BZ2-BZ7)  
A mixture of 2-(prop-2-in-1-yl)-1,3-benzothiazole BZ1 (1.5 g, 0.01 
mol), Paraformaldehyde (0.5 g, 0.015 mol), the cyclic amine around 
(0.01 mol), and a catalytic amount of Cuprous chloride (0.03 g), in 
Peroxide-free 1,4-Dioxane (30 ml) was stirred and refluxed for 1 h. 
After cooling, the insoluble residue was removed by filtration then 
the solvent was distilled off under reduced pressure. Ethanol (30 ml) 
was added to the residue, and then ethanol was evaporated under 
reduced pressure. What residue left was dissolved in the least 
amount of ethanol, precipitated with water, filtered and dried to 
afford Mannich bases BZ2, BZ3, BZ4, BZ5, BZ6, BZ7 (Fig.3). Physical 
and spectral data for the resulting compounds (BZ1-BZ7) are listed 
below in the results.  
 
 
Fig. 3: Synthesis of t-amino [but-2-yn-1-yl]-1, 3-benzothiazole 
derivatives (BZ2-BZ7) 
 
Synthesis of 2-[4-(pyrrolidin-1-yl) but-2-yn-1-yl]-1, 3-
benzothiazole (BZ2) 
The title compound BZ2 was synthesized, using a similar procedure 
to that described for the preparation of 2-{4-(t-amino)-2-(but-2-yn-
1-yl)}-1,3-benzothiazole derivatives (BZ2-BZ7) in 1.4 g, 54% yield as 
orange powder; m. p: (157-159 oC). IR (KBr cm-1): 2913 (ArH, 
stretch), 3030, 2357 (C≡C, stretch), 1602, 1414 (Ar, C=C, stretch), 
1252, 1136 (Ar, C=C, bending), 866, 759, (ArH, bending). 1H-NMR 
(DMSO-d6): δ, 1.6-1.7 (m, various proton of cyclic amine), 2.4 (s, 2H, 
C-CH2-N), 3.8 (s, 2H, CH2-C), 6.6-7.2 (m, 4H, ArH).  
Synthesis of 2-[4-(2-methylpiperidin-1-yl) but-2-yn-1-yl]-1, 3-
benzothiazole (BZ3) 
The title compound BZ3 was synthesized, using a similar procedure 
to that described for the preparation of 2-{4-(t-amino)-2-(but-2-yn-
1-yl)}-1,3-benzothiazole derivatives (BZ2-BZ7) in 1.5 g, 52% yield as 
orange powder; m. p (130-134 oC). IR (KBr cm-1): 2915 (Ar, C-H 
stretch), 2800 (Ar, C-H stretch), 1480 (Ar, C=C stretch), 1250 (Ar, C-
N, stretch), 1025 (Ar, C-N, stretch), 850 (Ar, C-H, bend), 750 (Ar, C-H, 
bend). 1H-NMR (DMSO-d6): δ, 1.1 (d, 3H, CH-CH3), 1.34, 1.5 (m, 
various proton of cyclic amine), 3.4 (s, 2H, C-CH2-N), 3.7 (s, 2H, CH2-
C), 6.6-7.2 (m, 4H, ArH).  
Synthesis of 2-[4-(piperidin-1-yl) but-2-yn-1-yl]-1, 3-benzo-
thiazole (BZ4) 
The title compound BZ4 was synthesized, using a similar procedure 
to that described for the preparation of 2-{4-(t-amino)-2-(but-2-yn-
1-yl)}-1,3-benzothiazole derivatives (BZ2-BZ7) in 1.73 g, 64% yield 
as orange powder; m. p: (148-150 oC). IR (KBr cm-1): 2915 (Ar, C-H, 
stretch), 2800 (Ar, C-H, stretch), 1480 (Ar, C=C, stretch), 1250 (Ar, C-
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N, stretch), 1025 (Ar, C-N, stretch), 850 (Ar, C-H, bend), 750 (Ar, C-H, 
bend). 1H-NMR (DMSO-d6): δ, 1.5 (m, various proton of cyclic amine), 
2.8 (s, 2H, C-CH2-N), 3.7 (s, 2H, CH2-C≡), 6.6-7.2 (m, 4H, ArH).  
Synthesis of 2-[4-(azepan-1-yl) but-2-yn-1-yl]-1,3-benzothiazole 
(BZ5)  
The title compound BZ5 was synthesized, using a similar procedure 
to that described for the preparation of 2-{4-(t-amino)-2-(but-2-yn-
1-yl)}-1,3-benzothiazole derivatives (BZ2-BZ7), in 1.44 g, 50% yield 
as orange powder; m. p: (122-125oC). IR (KBr cm-1): 2915 (Ar, C-H, 
stretch), 2800 (Ar, C-H, stretch), 1480 (Ar, C=C, stretch), 1250 (Ar, C-
N, stretch), 1025 (Ar, C-N, stretch), 850 (Ar, C-H, bend), 750 (Ar, C-H, 
bend). 1H-NMR (DMSO-d6): δ, δ 1.6-1.7 (m, various proton of cyclic 
amine), 2.4 (s, 2H, C-CH2-N), 3.6 (s, 2H, CH2-C), 6.6-7.2 (m, 4H, ArH). 
13C-NMR (DMSO-d6): δ, 26 (C[20]), 28 (C[19]), 32 (C[17,18]), 66 
(C[13,15,16]), 86 (C[11,12]), 114 (C3), 117 (C4), 120 (C6), 123 (C5), 
132 (C2), 153 (C1), 174 (C8), 55 (C[10]).  
Elemental analysis: Calcd. for C17H20N2S: C, 67.97%; H, 6.71%; N, 
9.32% found C, 66.3%; H, 5.89%; N, 9.3%.  
Synthesis of 2-[4-(4-methylpiperazin-1-yl) but-2-yn-1-yl]-1, 3-
benzothiazole (BZ6)  
The title compound BZ6 was synthesized, using a similar procedure 
to that described for the preparation of 2-{4-(t-amino)-2-(but-2-yn-
1-yl)}-1, 3-benzothiazole derivatives (BZ2-BZ7); in 1.75 g, 64% yield 
as orange powder; m. p: (166-170 oC). IR (KBr cm-1): 2915 (Ar, C-H, 
stretch), 2800 (Ar, C-H, stretch), 1480 (Ar, C=C, stretch), 1250 (Ar, C-
N, stretch), 1025 (Ar, C-N, stretch), 850 (Ar, C-H, bend), 750 (Ar, C-H, 
bend). 1H-NMR (DMSO-d6): δ, 1.8-2.1 (m, various proton of cyclic 
amine), 2.5 (s, 2H, C-CH2-N), 3.7 (s, 2H, CH2-C), 6.6-7.2 (m, 4H, ArH).  
Synthesis of 2-[4-(2, 6-dimethylpiperidin-1-yl) but-2-yn-1-yl]-1, 
3-benzothiazole (BZ7) 
The title compound BZ7 was synthesized, using a similar procedure 
to that described for the preparation of 2-{4-(t-amino)-2-(but-2-yn-
1-yl)}-1,3-benzothiazole derivatives (BZ2-BZ7), in 1.83 g, 63% yield 
as orange powder; m. p: (160-163 oC). IR (KBr cm-1): 2915 (Ar, C-H, 
stretch), 2800 (Ar, C-H, stretch), 1480 (Ar, C=C, stretch), 1250 (Ar, C-
N, stretch), 1025 (Ar, C-N, stretch), 850 (Ar, C-H, bend), 750 (Ar, C-H, 
bend). 1H-NMR (DMSO-d6): δ, 1.1 (d, 6H, CH-CH3), 1.4, 1.5, 1.7, 1.8, 
1.9 (m, various proton of cyclic amine), 3.4 (s, 2H, C-CH2N), 4.2 (s, 
2H, CH2-C), 7-7.6 (m, 4H, ArH).13C-NMR (DMSO-d6): δ, 23, 25, 35 
(various C of cyclic amine), 66 (C-N), 80, 81 (C≡C), 114, 117, 120, 
123, 132, 153 (Ar, C), 174 (N=C-S).  
Antimicrobial activity testing 
All the newly synthesized compounds 2-{4-(t-amino)-2-(but-2-yn-1-
yl)}-1,3-benzothiazole derivatives (BZ2-BZ7) were tested for in vitro 
antimicrobial activity, by the agar well diffusion method 13 
measuring the inhibition zone diameter, using 105 CFU/ml microbial 
inoculum and 0.1 ml of serial compounds dilution, and by 
determination of minimum inhibitory concentration (MIC) [13], the 
minimum bactericidal concentration (MBC) and minimum fungicidal 
concentration (MFC) were also recorded against the selected 
microorganisms. The synthesized compounds were screened for 
antimicrobial activity against two Gram-negative microorganisms E. 
coli (ATCC 8739) and P. aeruginosa (ATCC 9027) and two Gram-
positive microorganisms S. aureus (ATCC 6538p) and B. subtilis 
(ATCC 6633), using Muller Hinton agar medium at 200, 100, 50, 25 
µg/ml concentrations. Screening of antifungal activity was done 
against C. albicans (ATCC 10231), using Sabouraud’s dextrose agar 
medium at 200, 100, 50, 25 µg/ml.  
Stock solutions of the compounds were first prepared by dissolving 
them in a solution of 30% DMSO in water. Then the solutions were 
diluted serially in the media (Muller Hinton Broth for bacteria and 
Sabouraud’s Dextrose Broth for fungi) so as to achieve the required 
concentrations of the compound ranging from 200-25 µg/ml. A 
solution of 30% DMSO in distilled water (D. W) was employed as a 
solvent control. The results of antimicrobial testing are reported and 
compared with those of standard drugs ciprofloxacin 5 µg/ml and 
fluconazole 500 µg/ml. The antimicrobial activity testing was done 
in triplicate.  
Statistical analysis  
Statistical analysis was carried out using Student's t-test by 
statistical packages for social science software (SPSS). Values are 
expressed as mean±SD and values of p<0.05 were considered 
statistically significant. The relationships between variables were 
calculated using Pearson Correlation Coefficients.  
RESULTS AND DISCUSSION 
Chemistry 
The designed compounds were prepared as shown in schemes (1 
and 2). Scheme 1 involved the alkylation of benzothiazole with 3-
bromo prop-1-yne (Propargyl bromide) in the presence of 
acetonitrile as a solvent under basic conditions. The reaction 
involves direct displacement of the anionic carbon in the thiazole 
ring on the propargyl bromide to generate 2-(prop-2-yn-1-yl)-1, 3-
benzothiazole BZ1. The Mannich reaction of 2-(prop-2-yn-1-yl)-1,3-
benzothiazole BZ1, Paraformaldehyde, appropriate cyclic amine, and 
a catalytic amount of Cuprous chloride in Peroxide-free 1,4-Dioxane 
was heated to 80 oC to yield the designed compounds (BZ2-BZ7). 
The yield obtained ranged from 52.4 to 60.75%. The proposed 
mechanism for Mannich reaction is shown (scheme 2), in order for 
Mannich reaction to proceed, a reactive immonium cations 
intermediates should be formed from the condensation of the 
formaldehyde and the appropriate amines (Schiff base formation). 
The attack of the carbanion in 2-(prop-2-yn-1-yl)-1, 3-benzothiazole 
cuprous salt on the Schiff base generates the desired Mannich 
products (BZ2-BZ7). The IR, 1H-NMR, 13C-NMR, DSC and elemental 
analysis were consistent with the assigned structures.  
 
 
Scheme 1: Alkylation reaction of benzothiazole moiety 
 
 
Scheme 2: Proposed Mannich reaction 
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Antimicrobial activity 
The newly synthesized compounds BZ2-BZ7 showed activity against 
all types of the tested microorganisms, after 24 h incubation at 37 oC 
for bacteria and after 48 h incubation at 37 oC for fungi, the diameter 
zone of inhibition was measured. Compound 2-[4-(pyrrolidin-1-
yl)but-2-yn-1-yl]-1,3-benzothiazole (BZ2) showed high 
antimicrobial activity against P. aeruginosa with a zone of inhibition 
diameter of 30, 27, 20 mm in concentrations of 200, 100, 50 µg/ml, 
respectively, in comparison with the positive control ciprofloxacin (5 
µg/ml) which gave 21 mm. Compound 2-[4-(piperidin-1-yl) but-2-
yn-1-yl]-1,3-benzothiazole (BZ4) in the concentration of 200 µg/ml 
showed higher antimicrobial activity against B. subtilis, with a zone 
diameter of 26 mm in comparison to ciprofloxacin (5 µg/ml) which 
gave 21 mm. The results obtained by comparing the MIC values 
for compounds BZ2-BZ7 with the MIC values of the positive 
control ciprofloxacin (5 µg/ml), we find that the MIC value of 
compound BZ5 against S. aureus is less than the MIC value of the 
positive control (15.62, 50 µg/ml respectively). The MIC of 
compound BZ7 against P. aeruginosa is less than that of the 
positive control ciprofloxacin in 5 µg/ml (31.25, 50 µg/ml 
respectively). The pattern of the results of antifungal screening 
was different from that of antibacterial evaluation. The results of 
antifungal screening showed the good antifungal activity of all 
the synthesized compounds against C. albicans. Compound 2-[4-
(azepan-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole BZ5 also showed the 
highest antifungal activity among the synthesized compounds. 
Compounds BZ2 and BZ5 had the lowest MIC value of 15.62 µg/ml 
(for both) among all the synthesized compounds. The antimicrobial 
results of the newly synthesized compounds BZ2-BZ7 showed a 
broad spectrum of antibacterial and antifungal activity as shown in 
the table (1) and table (2). 
  
Table 1: The diameter of the zone of inhibition (in mm) of compounds BZ2-BZ7 at 200µg/ml concentration. 
C. albicans P. aeruginosa  E. coli  B. subtilis S. aureus Compound 
200  200   200 200  200  Concentration 
32±1.00 30±0.58 30±0.00 23±1.00 27±0.58 BZ2 
30±0.00 28±0.00 27±1.15 24±0.00 25±1.00 BZ3 
27±0.58 26±0.58 25±0.5  26±0.58 28±0.58 BZ4 
21±0.58 24±2.00 18±0.58 24±0.58 27±1.53 BZ5 
19±1.53 18±0.58 17±1.53 20±1.53 19±0.58 BZ6 
20±0.00 19±1.53 18±1.73 19±1.00 17±0.00 BZ7 
- 21±0.00 30±1.53 21±1.73 30±0.58 Ciprofloxacin (5µg/ml) 
30±0.58 - - - - Fluconazole (500 µg/ml) 
0 0 0 0 0 Negative control 
Values are mean±SD (n=3). 
BZ2: 2-{4-(t-amino)-2-(but-2-yn-1-yl)}-1, 3-benzothiazole derivatives 2-[4-(pyrrolidin-1-yl)but-2-yn-1-yl]-1,3-benzothiazole  
BZ3: 2-[4-(2-methylpiperidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ4: 2-[4-(piperidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ5: 2-[4-(azepan-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ6: 2-[4-(4-methylpiperazin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ7: 2-[4-(2, 6-dimethylpiperidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
 
Table 2: Minimum inhibitory concentration (MIC) of compounds (BZ2-BZ7) in µg/ml against S. aureus, B. subtilis, E. coli, P. aeruginosa and 
C. albicans 
C. albicans P. aeruginosa E. coli B. subtilis S. aureus Compound 
MIC/MFC (µg/ml)  MIC/MBC  (µg/ml) MIC/MBC (µg/ml) MIC/MBC (µg/ml)  MIC/MBC (µg/ml) . 
62.5/(125) 31.25/(62.5) 31.25/(62.5) 62.5/(125) 62.5/(125) BZ2 
62.5/(125) 31.25/(62.5) 31.25/(62.5) 31.25/(62.5) 62.5/(125) BZ3 
125/(250) 62.5/(125) 62.5/(125) 31.25/(62.5) 62.5/(125) BZ4 
62.5/(125) 62.5/(125) 62.5/(125) 31.25/(62.5) 15.62/(31.25) BZ5 
62.5/(125) 125/(250) 125/(250) 62.5/(125) 125/(250) BZ6 
31.25/(62.5)  125/(250) 125/(250) 31.25/(62.5) 125/(250) BZ7 
- 50 25 25 50 ciprofloxacin 
(5 µg/ml) 
8 - - - - fluconazole  
(500 µg/ml) 
- - - - - Negative control 
 
BZ2: 2-{4-(t-amino)-2-(but-2-yn-1-yl)}-1, 3-benzothiazole derivatives 2-[4-(pyrrolidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ3: 2-[4-(2-methylpiperidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ4: 2-[4-(piperidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ5: 2-[4-(azepan-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ6: 2-[4-(4-methylpiperazin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
BZ7: 2-[4-(2, 6-dimethylpiperidin-1-yl) but-2-yn-1-yl]-1, 3-benzothiazole  
MIC: Minimum inhibitory concentration. 
MBC: Minimum bactericidal concentration. 
MFC: Minimum fungicidal concentration 
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It was clear that there is variability in the susceptibilities of the 
different microorganisms to the different tested compounds and 
variability in the antibacterial activity, according to the method of 
investigation (agar diffusion method or broth dilution method). 
Many factors may influence the results, of these is the diffusion of 
the compound into the agar medium, which affected by the 
solubility of the compound [13] and the molecular weight of the 
compound, compounds with poor water solubility diffuse into the 
agar medium with difficulty giving smaller zone of inhibition, 
reported as low antimicrobial activity, the results obtained are 
often inadequate in comparison with the results of the broth 
dilution test which lacks these difficulties [13]. The good 
antibacterial activity of the compounds 2-[4-(azepan-1-yl) but-2-
yn-1-yl]-1,3-benzothiazole (BZ5) against Gram-positive bacteria is 
attributed to the lipophilicity and steric effect due to the large size 
of azepan and methyl piperidine groups respectively. The steric 
effect may exert physical pressure on the cell wall of Gram-
positive bacteria, and the lipophilicity effect may facilitate the 
diffusion of the compound through the cell wall. The outer 
membrane of the Gram-negative bacteria which characterize them 
from Gram-positive bacteria consists mainly of lipopolysaccharide, 
lipoproteins, and phospholipids, so the lipophilicity facilitated the 
entry of the compound into the microorganism which related to its 
antibacterial activity against Gram-negative bacteria.  
Substitution on a piperidine ring with a methyl group, lead to 
enhanced antimicrobial activity against Gram-negative bacteria 
(compound 2-[4-(2-methylpiperidin-1-yl) but-2-yn-1-yl]-1, 3-
benzothiazole (BZ3) when compared to compound BZ4. Also, 
disubstitution on ortho position of the piperidine ring with a 
methyl group increased the antibacterial activity (compound 2-[4-
(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]-1,3-benzothiazole BZ7), 
in comparison with compound 2-[4-(piperidin-1-yl)but-2-yn-1-yl]-
1,3-benzothiazole BZ4 against P. aeruginosa. Compound 2-[4-
(azepan-1-yl) but-2-yn-1-yl]-1,3-benzothiazole BZ5 also showed 
the highest antifungal activity among the synthesized compounds, 
due to steric and lipophilicity effects of the large azepan group. 
The compounds possessed a broad spectrum of antimicrobial 
activity against the tested microorganisms and displayed similar 
antimicrobial activity against fungi, as bacteria, demonstrated by 
similar MIC values against the tested microorganism. Another 
rationalization for these compounds with the selectivity to fungal 
sites of action, such as inhibition of Squalene epoxidase [14-16], 
CYP-450 [14, 17], and others [14] more than to those associated 
with the bacterial transpeptidase enzyme or blockade of protein 
synthesis. Further investigation may verify these points.  
CONCLUSION 
In conclusion, we have reported the synthesis of novel series of 
amino acetylenic benzothiazole derivatives. These amino acetylenic 
benzothiazole derivatives showed promising activity against Gram 
positive bacteria, Gram negative bacteria, and fungi. Compound BZ5 
showed the highest antibacterial activity against S. aureus among all 
the compounds with a MIC value of 15.62 µg/ml while; Compound 
BZ7 exhibited the highest antibacterial activity against P. aeruginosa 
with a MIC value of 31.25 µg/ml. The data on antimicrobial and 
antifungal activity generated from this investigation merit the 
generation of new derivatives amino acetylenic benzothiazoles with 
greater potency.  
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